Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021

SELL
$5.65 - $7.47 $446,451 - $590,264
-79,018 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$6.99 - $9.26 $591,360 - $783,405
-84,601 Reduced 51.71%
79,018 $622,000
Q3 2020

Nov 16, 2020

SELL
$8.49 - $19.54 $2.14 Million - $4.92 Million
-251,536 Reduced 60.59%
163,619 $1.39 Million
Q2 2020

Aug 14, 2020

SELL
$7.44 - $11.29 $18.7 Million - $28.4 Million
-2,512,197 Reduced 85.82%
415,155 $4.32 Million
Q1 2020

May 15, 2020

SELL
$6.94 - $14.22 $2.77 Million - $5.68 Million
-399,141 Reduced 12.0%
2,927,352 $27.4 Million
Q4 2019

Feb 14, 2020

BUY
$7.99 - $37.6 $1.19 Million - $5.59 Million
148,733 Added 4.68%
3,326,493 $26.7 Million
Q3 2019

Nov 14, 2019

BUY
$19.17 - $27.4 $8.78 Million - $12.6 Million
458,053 Added 16.84%
3,177,760 $65.2 Million
Q2 2019

Aug 14, 2019

SELL
$22.93 - $42.84 $2.56 Million - $4.79 Million
-111,800 Reduced 3.95%
2,719,707 $71 Million
Q1 2019

May 15, 2019

BUY
$32.69 - $47.91 $19.4 Million - $28.5 Million
593,900 Added 26.54%
2,831,507 $110 Million
Q4 2018

Feb 14, 2019

SELL
$37.1 - $50.11 $1.32 Million - $1.79 Million
-35,700 Reduced 1.57%
2,237,607 $94.1 Million
Q3 2018

Nov 14, 2018

BUY
$36.35 - $55.2 $1.05 Million - $1.59 Million
28,800 Added 1.28%
2,273,307 $114 Million
Q2 2018

Aug 14, 2018

BUY
$33.85 - $50.65 $233,565 - $349,485
6,900 Added 0.31%
2,244,507 $85.9 Million
Q1 2018

May 15, 2018

BUY
$32.45 - $54.7 $924,825 - $1.56 Million
28,500 Added 1.29%
2,237,607 $0
Q4 2017

Feb 14, 2018

SELL
$21.8 - $39.35 $1.28 Million - $2.31 Million
-58,600 Reduced 2.58%
2,209,107 $77.5 Million
Q3 2017

Nov 14, 2017

BUY
$16.4 - $25.05 $37.2 Million - $56.8 Million
2,267,707
2,267,707 $49.3 Million

Others Institutions Holding WVE

About Wave Life Sciences Ltd.


  • Ticker WVE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 86,820,096
  • Market Cap $1.07B
  • Description
  • Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional pr...
More about WVE
Track This Portfolio

Track Redmile Group, LLC Portfolio

Follow Redmile Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.